Abstract 2542: Preclinical studies of novel phosphonium salts with broad-spectrum activity

• Published in: Cancer research (Chicago, Ill.) Vol. 71; no. 8_Supplement; p. 2542
• Main Authors: Millard, Melissa, Pathania, Divya, Shabaik, Yumna, Taheri, Laleh, Deng, Jinxia, Neamati, Nouri
• Format: Journal Article
• Language: English
• Published: 15.04.2011
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2011-2542

Abstract Proliferation under selective pressures exerted by an unstable microenvironment, requires tumor cells employ adaptive mechanisms that confer growth advantage. Adaptation to adverse conditions results in cellular phenotypes that typify neoplastic transformation and offer unique opportunities for selective targeting of cancer cells. Agents that target tumor cell mitochondria with high selectivity hold clinical significance due to the adaptive, modulatory and essential role of this organelle in cancer cell energy production, metabolism and apoptosis. To this end, we have identified a series of novel, mitochondriotropic phosphonium salts, (TP compounds), that have shown broad-spectrum anti-cancer and anti-angiogenic activity in preclinical evaluation. A high-throughput MTT-based screen of over 10,000 drug-like small molecules for anti-proliferative activity identified the phosphonium salts TP187, 197 and 421 and numerous close analogues as having IC50 concentrations in the sub-micromolar range. TP treatment induced cell cycle arrest, lowered oxygen consumption, and increased mitochondrial superoxide production. Administered as single agents in a mouse model of human breast cancer, TP compounds significantly decreased tumor growth with no observed toxicities. Protein microarray data demonstrated significant down-regulation of integrin and growth factor mediated signaling pathways governing key processes including cancer cell survival, proliferation and tumor angiogenesis. At low micromolar concentrations, TP compounds prevented integrin-mediated cell adhesion to fibronectin and vitronectin coated substrates and tumor cell haptotaxsis on vitronectin coated boyden chambers. Similar concentrations of TP compound also prevented growth factor induced endothelial cell tube formation in 3-D culture using basement membrane extracts. Taken together, these results suggest that as mitochondria-targeted agents, TP compounds act to inhibit tumor cell proliferation and angiogenic capacity. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2542. doi:10.1158/1538-7445.AM2011-2542